查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612713

CD 抗原癌症治療市場：按治療類型、CD 抗原類型、癌症類型、最終用戶 - 全球預測 2025-2030

CD Antigen Cancer Therapy Market by Therapy Type, Type of CD Antigens, Type of Cancer, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

CD抗原癌症治療市場2023年估值為104.8億美元，預計2024年將達到110.9億美元，複合年成長率為6.17%，到2030年將達到159.4億美元。

CD 抗原癌症治療涉及靶向分化簇 (CD) 分子，這些分子是在免疫反應中發揮重要作用的細胞表面蛋白。這些治療方法在癌症治療中至關重要，因為它們可以精確靶向癌細胞，同時最大限度地減少對健康組織的損害。對 CD 抗原療法的需求源於其提高癌症患者生存率和生活品質的潛力，使其成為個人化醫療時代的一種有前途的方法。它已應用於多種癌症類型，包括淋巴瘤和白血病，其中 CD19 和 CD20 等 CD 抗原是有效標靶。主要最終用戶包括推動該領域進步的醫院、癌症研究機構和生技公司。

主要市場統計
基準年[2023] 104.8億美元
預測年份 [2024] 110.9億美元
預測年份 [2030] 159.4億美元
複合年成長率（%） 6.17%

市場洞察指出了幾個成長要素，例如癌症發病率的增加、生物技術的進步以及政府促進癌症研究的支持政策。新的商機在於CD抗原療法的應用從血液癌擴展固體癌，以及針對多種CD抗原的雙特異性抗體和CAR-T細胞療法的進展。為了利用這些機會，公司必須投資強大的研發開發平臺和策略聯盟。然而，市場面臨挑戰，包括高昂的治療開發成本、嚴格的監管環境以及潛在的不良免疫反應。癌症異質性的複雜性也產生了局限性，這可能會降低目標療效。

有前景的創新途徑包括探索 CD 抗原療法和免疫療法的聯合治療，以及整合人工智慧主導的方法以提高診斷準確性。對 CD 的新標靶和改進的交付機制的研究可以進一步釋放該市場的潛力。市場動態是動態的和競爭性的，要求相關人員保持敏捷，專注於專利策略，並促進合作以維持市場影響。實施數位健康技術來簡化臨床試驗流程並促進以患者為中心的結果可以顯著增強業務成長和市場差異化。

市場動態：揭示快速發展的 CD 抗原癌症治療市場的關鍵市場洞察

CD 抗原癌症治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球癌症發生率上升
    • 對個人化醫療的興趣日益濃厚
  • 市場限制因素
    • CD抗原治療費用高
  • 市場機會
    • 生物技術不斷進步，提高 CD 抗原治療的功效
    • 增加政府對癌症研究的資助和支持
  • 市場挑戰
    • 與 CD 抗原治療相關的替代技術的出現

波特五力：開拓 CD 抗原癌症治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 CD 抗原癌症治療市場的外部影響

外部宏觀環境因素在塑造 CD 抗原癌症治療市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解CD抗原癌症治療市場的競爭狀況

CD抗原癌症治療市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 CD 抗原癌症治療市場供應商的績效評估

FPNV定位矩陣是評估CD抗原癌症治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製 CD 抗原癌症治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，CD 抗原癌症治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地各種癌症的發生率正在上升
      • 個人化醫療的趨勢日益成長
    • 抑制因素
      • CD抗原治療高成本
    • 機會
      • 提高 CD 抗原治療功效的生物技術進步
      • 增加政府對癌症研究的資助和支持
    • 任務
      • 與 CD 抗原治療相關的替代技術的出現
  • 市場區隔分析
    • 治療類型：增加抗體藥物複合體的使用，以盡量減少化療對健康細胞的影響
    • 最終使用者：提高提供全面照護的癌症治療中心 CD 抗原癌症治療的可近性
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 CD 抗原癌症治療市場（依治療類型）

  • 抗體藥物複合體
  • 雙特異性 T 細胞接合器
  • 嵌合體抗原受體T細胞療法
  • 單株抗體
  • 放射免疫治療

第7章CD抗原癌症治療市場（依CD抗原類型分類）

  • 通用抗原
  • 新抗原

第8章依癌症類型分類的CD抗原癌症治療市場

  • 乳癌
  • 白血病
  • 肺癌
  • 淋巴瘤
  • 多發性骨髓瘤
  • 攝護腺癌

第 9 章 CD 抗原癌症治療市場：依最終用戶分類

  • 癌症治療中心
  • 醫院
  • 調查機構
  • 專科診所

第10章北美和南美CD抗原癌症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區CD抗原癌症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲CD抗原癌症治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Coeptis Therapeutics 在 SITC 2023 上宣布 SNAP-CAR T 細胞癌症治療的進展
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Illumina, Inc.
  • Incyte Corporation
  • Jazz Pharmaceuticals PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Seagen Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-9A2BA9536662

The CD Antigen Cancer Therapy Market was valued at USD 10.48 billion in 2023, expected to reach USD 11.09 billion in 2024, and is projected to grow at a CAGR of 6.17%, to USD 15.94 billion by 2030.

CD Antigen Cancer Therapy involves targeting cluster of differentiation (CD) molecules, cell surface proteins that play crucial roles in immune responses. These therapies are pivotal in oncology as they enable precise targeting of cancer cells while minimizing damage to healthy tissue. The necessity of CD antigen therapies stems from their potential to improve survival rates and quality of life for cancer patients, offering a promising approach in the era of personalized medicine. Applications extend across various cancer types, including lymphomas and leukemias, where CD antigens like CD19 and CD20 serve as effective targets. Key end-user segments include hospitals, cancer research institutes, and biotech companies that drive advancements in this field.

KEY MARKET STATISTICS
Base Year [2023] USD 10.48 billion
Estimated Year [2024] USD 11.09 billion
Forecast Year [2030] USD 15.94 billion
CAGR (%) 6.17%

Market insights point to several growth factors, such as increasing cancer prevalence, advancements in biotechnology, and supportive governmental policies promoting cancer research. Emerging opportunities lie in expanding applications of CD antigen therapies beyond hematological cancers to solid tumors, as well as advancements in bispecific antibodies and CAR-T cell therapies targeting multiple CD antigens. It's vital for companies to invest in robust R&D pipelines and strategic collaborations to capitalize on these opportunities. However, the market faces challenges, including high costs of therapy development, stringent regulatory landscapes, and potential adverse immune responses. Limitations also arise from the complexity of cancer heterogeneity, which may reduce targeting efficacy.

For innovation, exploring combination therapies with CD antigenial therapeutics and immunotherapies or integrating AI-driven approaches to enhance diagnostic precision offers promising avenues. Research into novel CD targets and improving delivery mechanisms can further unlock potential in this market. As the CD antigen cancer therapy market is dynamic and competitive, stakeholders must remain agile, focusing on patent strategies and fostering collaborations to sustain market presence. Embracing digital health technologies to streamline clinical trial processes and promote patient-centric outcomes can significantly enhance business growth and market differentiation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving CD Antigen Cancer Therapy Market

The CD Antigen Cancer Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of a number of cancer inccidences worldwide
    • Increasing inclination toward personalized medicines
  • Market Restraints
    • High costs of CD antigen therapies
  • Market Opportunities
    • Growing technological advancements in biotechnology that improve the effectiveness of CD antigen therapies
    • Increased government funding and support for cancer research
  • Market Challenges
    • Emergence of alternative technologies associated with CD antigen therapies

Porter's Five Forces: A Strategic Tool for Navigating the CD Antigen Cancer Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the CD Antigen Cancer Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the CD Antigen Cancer Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the CD Antigen Cancer Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the CD Antigen Cancer Therapy Market

A detailed market share analysis in the CD Antigen Cancer Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the CD Antigen Cancer Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the CD Antigen Cancer Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the CD Antigen Cancer Therapy Market

A strategic analysis of the CD Antigen Cancer Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the CD Antigen Cancer Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceuticals, Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Exelixis, Inc., Genmab A/S, Gilead Sciences, Inc., Illumina, Inc., Incyte Corporation, Jazz Pharmaceuticals PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi, Seagen Inc., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the CD Antigen Cancer Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Type, market is studied across Antibody-Drug Conjugates, Bi-specific T-cell Engagers, Chimeric Antigen Receptor T-cell Therapy, Monoclonal Antibodies, and Radioimmunotherapy.
  • Based on Type of CD Antigens, market is studied across Common Antigens and Emerging Antigens.
  • Based on Type of Cancer, market is studied across Breast Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, and Prostate Cancer.
  • Based on End-user, market is studied across Cancer Treatment Centers, Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of a number of cancer inccidences worldwide
      • 5.1.1.2. Increasing inclination toward personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of CD antigen therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing technological advancements in biotechnology that improve the effectiveness of CD antigen therapies
      • 5.1.3.2. Increased government funding and support for cancer research
    • 5.1.4. Challenges
      • 5.1.4.1. Emergence of alternative technologies associated with CD antigen therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Type: Growing usage of antibody-drug conjugates to minimize the impact of the chemotherapy on healthy cells
    • 5.2.2. End-user: Increasing accessibility of CD antigen cancer therapy in cancer treatment centers as they offer comprehensive care
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. CD Antigen Cancer Therapy Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Antibody-Drug Conjugates
  • 6.3. Bi-specific T-cell Engagers
  • 6.4. Chimeric Antigen Receptor T-cell Therapy
  • 6.5. Monoclonal Antibodies
  • 6.6. Radioimmunotherapy

7. CD Antigen Cancer Therapy Market, by Type of CD Antigens

  • 7.1. Introduction
  • 7.2. Common Antigens
  • 7.3. Emerging Antigens

8. CD Antigen Cancer Therapy Market, by Type of Cancer

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Leukemia
  • 8.4. Lung Cancer
  • 8.5. Lymphoma
  • 8.6. Multiple Myeloma
  • 8.7. Prostate Cancer

9. CD Antigen Cancer Therapy Market, by End-user

  • 9.1. Introduction
  • 9.2. Cancer Treatment Centers
  • 9.3. Hospitals
  • 9.4. Research Institutes
  • 9.5. Specialty Clinics

10. Americas CD Antigen Cancer Therapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific CD Antigen Cancer Therapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa CD Antigen Cancer Therapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Coeptis Therapeutics to Unveil Advances in SNAP-CAR T-Cell Cancer Therapy at SITC 2023
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Biogen Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Celgene Corporation
  • 9. Eli Lilly and Company
  • 10. Exelixis, Inc.
  • 11. Genmab A/S
  • 12. Gilead Sciences, Inc.
  • 13. Illumina, Inc.
  • 14. Incyte Corporation
  • 15. Jazz Pharmaceuticals PLC
  • 16. Johnson & Johnson
  • 17. Merck & Co., Inc.
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Regeneron Pharmaceuticals, Inc.
  • 21. Roche Holding AG
  • 22. Sanofi
  • 23. Seagen Inc.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. CD ANTIGEN CANCER THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CD ANTIGEN CANCER THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CD ANTIGEN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CD ANTIGEN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CD ANTIGEN CANCER THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CD ANTIGEN CANCER THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY BI-SPECIFIC T-CELL ENGAGERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COMMON ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY EMERGING ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. CD ANTIGEN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. CD ANTIGEN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2023